A 2026 retrospective case series of 22 adults with treatment-resistant depression and comorbid PTSD found that trauma re-experiencing during intranasal esketamine disappeared over later sessions in 72.7% of patients, while 27.3% stopped esketamine because the flashbacks persisted.1 Research Highlights Flashbacks usually faded, but not always: In 16 of 22 patients (72.7%), esketamine-related trauma re-experiencing disappeared …
PTSD and major depressive disorder co-occur in roughly half of patients with either diagnosis, and the comorbid presentation is more severe than either alone. The mechanistic question has been whether comorbidity reflects synergistic biology or simple symptom additivity. A 2026 rat-model study by Jiang and colleagues tests this directly, finding that PTSD-MDD comorbid rats show …
Ketamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors and clinics: at single sub-anesthetic doses, in supervised settings, addiction risk is minimal. A new case report in BJPsych Open documents a patient for whom that pitch failed catastrophically — and …
The intersection of mental health treatment and pharmacology is witnessing a remarkable shift with the growing interest in ketamine and classic psychedelics like psilocybin for their rapid and sustained antidepressant effects. Unlike traditional antidepressants, these substances offer hope for those with treatment-resistant depression by potentially transforming treatment paradigms. However, it remains somewhat unclear as to …
Depression is a complex mental health condition that significantly affects an individual’s emotional and physical well-being. Recent advances in neuroimaging have provided deeper insights into how major depressive disorder (MDD) alters brain structures, particularly the hippocampus and amygdala, and how treatments like ketamine can potentially reverse these changes. A new study using 3T and 7T …
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …
Treatment-resistant depression (TRD) represents a significant challenge in mental health care, often leaving patients and clinicians in a difficult position after traditional treatments fail. Recent studies, including a prospective, observational study at a leading medical center, have brought new hope in the form of esketamine, a novel antidepressant. Highlights: Esketamine’s Mechanism: Esketamine, the S-enantiomer of …